News
Keytruda Approved as First-Line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer
The approval was based on data from the phase 3 KEYNOTE-826 trial.
Your search for bevacizumab returned 137 results
ESMO 2021, News
Immunotherapy Significantly Improved Survival in Recurrent/Metastatic Cervical Cancer
The checkpoint inhibitor cemiplimab improved survival in patients with recurrent/metastatic cervical carcinoma compared with single-agent chemotherapy.
ESMO 2021, News
Adding Bevacizumab to Erlotinib Prolongs PFS in Non-Squamous Non-Small Cell Lung Cancer
There was no improvement in overall survival with bevacizumab.
ESMO 2021, News
Pembrolizumab Plus Chemo ± Bevacizumab Prolonged Survival in Cervical Cancer
Pembrolizumab plus chemotherapy with or without bevacizumab could be a new standard of care for first-line therapy in metastatic cervical cancer.
News
Some Cancer Drugs Without Proven Benefit Still Recommended
Six of 18 indications remain on label for cancer drugs that failed to improve primary end point in trials after receiving accelerated approval
Clinical Charts
FDA-Approved Biosimilars
A comparative list of biosimilars approved by the FDA including their reference products, dosage forms and indications.
Clinical Charts
FDA-Approved Ovarian Cancer Treatments
FDA-Approved treatment options for individuals with ovarian cancer including dosing.
Clinical Charts
FDA-Approved Non-Small Cell Lung Cancer (NSCLC) Treatments
Chemotherapeutic and biologic agents for the treatment of non-small cell lung cancer (NSCLC).
Clinical Charts
FDA-Approved Colorectal Cancer Treatments
Colorectal cancer treatment regimen chart.
Drug Monograph
ZIRABEV
Bevacizumab-bvzr 100mg, 400mg; per vial; soln for IV infusion after dilution; preservative-free.
